Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Marquez, Béatrice ^a,c   Ameye, Geneviève ^b   Vallet, Coralie M ^a   Tulkens, Paul M ^a   Poirel, Hélène A ^b   van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C4; CIPROFLOXACIN; UNCLASSIFIED DRUG; ABCC4 PROTEIN, MOUSE; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DNAJC3 PROTEIN, MOUSE; HEAT SHOCK PROTEIN 40; MULTIDRUG RESISTANCE PROTEIN;

ABCC4 GENE; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CHROMOSOME 14; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EXPOSURE; EMBRYO; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PARTIAL TRISOMY; REVERTANT; ANIMAL; CELL LINE; CELL STRAIN HEK293; CHEMISTRY; CHROMOSOME; CYTOGENETICS; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; KARYOTYPING; METABOLISM;

ANIMALS; ANTI-INFECTIVE AGENTS; CELL LINE; CHROMOSOMES; CIPROFLOXACIN; CYTOGENETICS; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TOPOISOMERASE INHIBITORS;

EID: 82655189169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028368     Document Type: Article

References (54)

1. Eckford PD, Sharom FJ, (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109: 2989-3011.
2. Marquez B, Van Bambeke F, (2011) ABC multidrug transporters: Target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 12: 600-620.
3. Lee W, Choi HI, Kim MJ, Park SY, (2008) Depletion of mitochondrial DNA up-regulates the expression of MDR1 gene via an increase in mRNA stability. Exp Mol Med 40: 109-117.
4. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, et al. (2008) Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98: 1515-1524.
5. Baker EK, Johnstone RW, Zalcberg JR, El Osta A, (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061-8075.
6. Albertson DG, (2006) Gene amplification in cancer. Trends Genet 22: 447-455.
7. Mottino AD, Catania VA, (2008) Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 14: 7068-7074.
8. Fojo T, (2007) Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 10: 59-67.
9. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, et al. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410.
10. Rund D, Azar I, Shperling O, (1999) A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol 457: 71-75.
11. Knutsen T, Mickley LA, Ried T, Green ED, du Manoir S, et al. (1998) Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 23: 44-54.
12. Choi HK, Yang JW, Roh SH, Han CY, Kang KW, (2007) Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 14: 293-303.
13. Russel FG, Koenderink JB, Masereeuw R, (2008) Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29: 200-207.
14. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67: 262-268.
15. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, et al. (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68: 4983-4989.
16. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, et al. (2008) Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 68: 1421-1429.
17. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, et al. (2008) Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 32: 799-809.
18. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, et al. (2005) Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 4: 547-553.
19. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, et al. (2009) Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114: 1383-1386.
20. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, et al. (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-1051.
21. Marquez B, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F, (2009) Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother 53: 2410-2416.
22. Tulkens PM, (1991) Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 10: 100-106.
23. Albertini S, Chetelat AA, Miller B, Muster W, Pujadas E, et al. (1995) Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis 10: 343-351.
24. Elsea SH, Osheroff N, Nitiss JL, (1992) Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J Biol Chem 267: 13150-13153.
25. Lynch A, Harvey J, Aylott M, Nicholas E, Burman M, et al. (2003) Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18: 345-353.
26. Gottesman MM, Cardarelli C, Goldenberg S, Licht T, Pastan I, (1998) Selection and maintenance of multidrug-resistant cells. Methods Enzymol 292: 248-258.
27. Michot JM, Heremans MF, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, et al. (2006) Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob Agents Chemother 50: 1689-1695.
28. Wielinga PR, Reid G, Challa EE, van der Heijden I, Van Deemter L, et al. (2002) Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62: 1321-1331.
29. Haslam IS, Wright JA, O'Reilly DA, Sherlock DJ, Coleman T, et al. (2011) Intestinal Ciprofloxacin Efflux; the Role of Breast Cancer Resistance Protein, BCRP (ABCG2). Drug Metab Dispos Epub ahead of print.
30. Slovak ML, Lothstein L, Horwitz SB, Trent JM, (1988) Molecular/cytogenetic alterations accompanying the development of multidrug resistance in the J774.2 murine cell line. Leukemia 2: 453-458.
31. Rao VK, Wangsa D, Robey RW, Huff L, Honjo Y, et al. (2005) Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. Cancer Genet Cytogenet 160: 126-133.
32. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, et al. (1993) Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53: 3221-3225.
33. Lepage P, Devault A, Gros P, (1993) Activation of the mouse mdr3 gene by insertion of retroviruses in multidrug-resistant P388 tumor cells. Mol Cell Biol 13: 7380-7392.
34. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T, (1997) Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 99: 1947-1957.
35. Helmrich A, Stout-Weider K, Hermann K, Schrock E, Heiden T, (2006) Common fragile sites are conserved features of human and mouse chromosomes and relate to large active genes. Genome Res 16: 1222-1230.
36. Drlica K, Malik M, Kerns RJ, Zhao X, (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52: 385-392.
37. Herbold BA, Brendler-Schwaab SY, Ahr HJ, (2001) Ciprofloxacin: in vivo genotoxicity studies. Mutat Res 498: 193-205.
38. Rosen JE, Schluter G, Williams GM, (1996) Lack of effects of ciprofloxacin and the topoisomerase II inhibitors, m-AMSA and nalidixic acid, on DNA repair in cultured rat liver cells. Toxicol Appl Pharmacol 140: 254-263.
39. Mitelman F, Kolnig AM, Strombeck B, Norrby R, Kromann-Andersen B, et al. (1988) No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32: 936-937.
40. Gorla N, Garcia OH, Larripa I, (1999) Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin. Toxicol Lett 104: 43-48.
41. Anupama M, Seiler JP, Murthy PB, (2010) A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods. Arch Toxicol 84: 411-420.
42. Mukherjee A, Sen S, Agarwal K, (1993) Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo. Mutat Res 301: 87-92.
43. Itoh T, Mitsumori K, Kawaguchi S, Sasaki YF, (2006) Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test. Mutat Res 603: 135-144.
44. Itoh S, Nakayama S, Shimada H, (2002) In vitro photochemical clastogenicity of quinolone antibacterial agents studied by a chromosomal aberration test with light irradiation. Mutat Res 517: 113-121.
45. European Medicines Agency (2009) Withdrawal assessment report for FACTIVE (International Nonproprietary Name: Gemifloxacin). Procedure No. EMEA/H/C/995 pp. 1-43.
46. Foroumadi A, Emami S, Rajabalian S, Badinloo M, Mohammadhosseini N, et al. (2009) N-Substituted piperazinyl quinolones as potential cytotoxic agents: structure-activity relationships study. Biomed Pharmacother 63: 216-220.
47. Rajabalian S, Foroumadi A, Shafiee A, Emami S, (2007) Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents. J Pharm Pharm Sci 10: 153-158.
48. Snyderman R, Pike MC, Fischer DG, Koren HS, (1977) Biologic and biochemical activities of continuous macrophage cell lines P388D1 and J774.1. J Immunol 119: 2060-2066.
49. Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM, (2004) Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother 48: 2673-2682.
50. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM, (2005) Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49: 2429-2437.
51. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
52. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 29: e45.
53. Lee JJ, Warburton D, Robertson EJ, (1990) Cytogenetic methods for the mouse: preparation of chromosomes, karyotyping, and in situ hybridization. Anal Biochem 189: 1-17.
54. Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, et al. (2009) Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 23: 125-133.